Circadian Regulation of mTOR by the Ubiquitin Pathway in Renal Cell Carcinoma

Abstract

Circadian clock systems regulate many biologic functions, including cell division and hormone secretion in mammals. In this study, we explored the effects of circadian control on the pivot cell growth regulatory mTOR, the activity of which is deregulated in tumor cells compared with normal cells. Specifically, we investigated whether the antitumor effect of an mTOR inhibitor could be improved by changing its dosing schedule in RenCa tumorbearing mice. Active, phosphorylated mTOR displayed a 24-hour rhythm, and levels of total mTOR protein (but not mRNA) also showed a circadian rhythm in RenCa tumor masses. Through investigations of the oscillation mechanism for mTOR expression, we identified the ubiquitination factor Fbxw7 as an mTOR regulator that oscillated in its expression in a manner opposite from mTOR. Fbxw7 transcription was regulated by the circadian regulator D-site-binding protein. Notably, administration of the mTOR inhibitor everolimus during periods of elevated mTOR improved survival in tumor-bearing mice. Our findings demonstrate that the circadian oscillation of mTOR activity is regulated by circadian clock systems, which influence the antitumor effect of mTOR inhibitors. Cancer Res; 74(2); 543-51. Ó2013 AACR.

Bisphenol AF as an Inducer of Estrogen Receptor β (ERβ): Evidence for Anti-estrogenic Effects at Higher Concentrations in Human Breast Cancer Cells

“…20) Membranes were photographed using the Chemi Doc XRS plus system (Bio-Rad, Hercules, CA, U.S.A.). Equal amounts of protein for each sample were confirmed by probing with actin.…”

Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression

“…Given the up-regulation of the mTOR pathway in many chemoresistant cancer [2] , mTOR inhibitors provide a logical solution to re-sensitize tumor cells to chemotherapy or to delay the development of resistance to treatment. Recent studies have demonstrated the effectiveness of sirolimus (rapamycin) in solid tumors, such as metastatic breast [3] , pancreatic [4] , and renal carcinomas [5] . Sirolimus is a first generation mTOR inhibitor [6][7][8] .…”

Molecular clocks and the human condition: approaching their characterization in human physiology and disease

“…An example of the functional relevance of target oscillation attained in mice has been that of mechanistic target of rapamycin (mTOR) [24]. Here, the survival rate of mice with xenograft tumours is conditioned by the time of administration of everolimus [25]. Similarly, we have found that while administration of indomethacin influences the microbiome, there is a reciprocal impact on indomethacin disposition, gut bacteria mediating its deglucuronidation.…”